trial

Lurasidone Effects on Tissue Glutamate in Schizophrenia

NCTId NCT02199743
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 35 (actual)
Sponsored by University of Texas Southwestern Medical Center
Primary completion 2016-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
35 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-02
Primary completion
2016-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LurasidoneHaloperidolPerphenazine

Sponsors

University of Texas Southwestern Medical CenterLead Sponsor
Sumitomo Pharmaceuticals AmericaCollaborator

Investigators

1
Carol A. Tamminga, M.D.Principal Investigator

Sites

1 total
Dallas, United States

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE4
Primary Completion Date
2016-06
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
Haloperidol
drug
Perphenazine
drug
lead_sponsor
University of Texas Southwestern Medical Center
company
collaborator
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Carol A. Tamminga, M.D.
person